16D0 Campling, Barbara - Thomas Jefferson University - Thomas Jefferson University
Dr. Campling

Barbara Campling, MD

Contact Dr. Campling

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests
  2. Current management of locally advanced head and neck cancer: The combination of chemotherapy with locoregional treatments
  3. Acute activation, desensitization and smoldering activation of human acetylcholine receptors
  4. Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab
  5. Choline transporter-like protein 4 (CTL4) links to non-neuronal acetylcholine synthesis
  6. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field Radiotherapy and concurrent chemotherapy
  7. Spontaneous smoking cessation before lung cancer diagnosis
  8. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
  9. The problem of platinum resistance
  10. A population-based study of lung carcinoma in Pennsylvania: Comparison of Veterans Administration and Civilian Populations
  11. Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer
  12. Topotecan in small cell lung cancer: First or second line?
  13. Clinical implication of p53 mutation in lung cancer
  14. Clinical implications of p53 mutations in lung cancer.
  15. Therapy and disease concepts: The history (and future?) of antimony in cancer
  16. Constitutive activation of Met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival
  17. Clinical and molecular features of small cell lung cancer
  18. The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer
  19. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels
  20. Enhanced anti-cancer activities of some derivatives of titanocene dichloride